News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
750,141 Results
Type
Article (68701)
Company Profile (281)
Press Release (681158)
Multimedia
Podcasts (122)
Webinars (16)
Section
Business (205437)
Career Advice (3065)
Deals (36187)
Drug Delivery (119)
Drug Development (85787)
Employer Resources (173)
FDA (16896)
Job Trends (15774)
News (354098)
Policy (34676)
Tag
Academia (2928)
Academic (2)
Accelerated approval (12)
Adcomms (30)
Allergies (105)
Alliances (51936)
ALS (119)
Alzheimer's disease (1569)
Antibody-drug conjugate (ADC) (172)
Approvals (16859)
Artificial intelligence (360)
Autoimmune disease (35)
Automation (19)
Bankruptcy (337)
Best Places to Work (12213)
BIOSECURE Act (22)
Biosimilars (133)
Biotechnology (193)
Bladder cancer (99)
Brain cancer (40)
Breast cancer (383)
Cancer (3020)
Cardiovascular disease (245)
Career advice (2598)
Career pathing (34)
CAR-T (204)
CDC (41)
Cell therapy (556)
Cervical cancer (24)
Clinical research (70166)
Collaboration (1083)
Company closure (3)
Compensation (655)
Complete response letters (34)
COVID-19 (2845)
CRISPR (66)
C-suite (357)
Cystic fibrosis (120)
Data (3068)
Decentralized trials (2)
Denatured (41)
Depression (67)
Diabetes (378)
Diagnostics (6752)
Digital health (24)
Diversity (10)
Diversity, equity & inclusion (45)
Drug discovery (162)
Drug pricing (140)
Drug shortages (33)
Duchenne muscular dystrophy (132)
Earnings (80505)
Editorial (48)
Employer branding (21)
Employer resources (153)
Events (116811)
Executive appointments (907)
FDA (18614)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (996)
Gene editing (145)
Generative AI (35)
Gene therapy (424)
GLP-1 (920)
Government (5103)
Grass and pollen (6)
Guidances (180)
Healthcare (20104)
HIV (44)
Huntington's disease (32)
IgA nephropathy (44)
Immunology and inflammation (180)
Immuno-oncology (8)
Indications (40)
Infectious disease (3037)
Inflammatory bowel disease (165)
Inflation Reduction Act (12)
Influenza (69)
Intellectual property (125)
Interviews (581)
IPO (16850)
IRA (49)
Job creations (4004)
Job search strategy (2167)
Kidney cancer (15)
Labor market (47)
Layoffs (573)
Leadership (26)
Legal (8243)
Liver cancer (84)
Longevity (12)
Lung cancer (423)
Lymphoma (211)
Machine learning (10)
Management (59)
Manufacturing (412)
MASH (97)
Medical device (13920)
Medtech (13925)
Mergers & acquisitions (20106)
Metabolic disorders (942)
Multiple sclerosis (104)
NASH (22)
Neurodegenerative disease (140)
Neuropsychiatric disorders (36)
Neuroscience (2301)
NextGen: Class of 2025 (7162)
Non-profit (4973)
Now hiring (25)
Obesity (478)
Opinion (283)
Ovarian cancer (102)
Pain (118)
Pancreatic cancer (122)
Parkinson's disease (200)
Partnered (23)
Patents (316)
Patient recruitment (172)
Peanut (55)
People (62238)
Pharmaceutical (68)
Pharmacy benefit managers (21)
Phase I (21708)
Phase II (30723)
Phase III (23000)
Pipeline (1682)
Policy (231)
Postmarket research (3061)
Preclinical (9568)
Press Release (70)
Prostate cancer (150)
Psychedelics (43)
Radiopharmaceuticals (273)
Rare diseases (525)
Real estate (6451)
Recruiting (70)
Regulatory (24023)
Reports (44)
Research institute (2614)
Resumes & cover letters (468)
Rett syndrome (10)
RNA editing (10)
RSV (56)
Schizophrenia (94)
Series A (172)
Series B (116)
Service/supplier (10)
Sickle cell disease (67)
Special edition (18)
Spinal muscular atrophy (163)
Sponsored (35)
Startups (3728)
State (1)
Stomach cancer (14)
Supply chain (81)
Tariffs (57)
The Weekly (79)
Vaccines (889)
Venture capital (56)
Weight loss (314)
Women's health (47)
Worklife (20)
Date
Today (95)
Last 7 days (381)
Last 30 days (1936)
Last 365 days (32547)
2025 (17671)
2024 (36332)
2023 (40853)
2022 (52106)
2021 (56970)
2020 (55865)
2019 (49441)
2018 (37526)
2017 (34407)
2016 (34444)
2015 (40180)
2014 (33918)
2013 (30058)
2012 (31630)
2011 (31441)
2010 (30425)
Location
Africa (1047)
Alabama (69)
Alaska (7)
Arizona (219)
Arkansas (14)
Asia (44147)
Australia (7752)
California (7497)
Canada (2357)
China (718)
Colorado (328)
Connecticut (338)
Delaware (194)
Europe (101798)
Florida (1135)
Georgia (256)
Hawaii (1)
Idaho (64)
Illinois (692)
India (29)
Indiana (364)
Iowa (15)
Japan (236)
Kansas (107)
Kentucky (31)
Louisiana (16)
Maine (67)
Maryland (1065)
Massachusetts (5667)
Michigan (259)
Minnesota (440)
Mississippi (3)
Missouri (99)
Montana (31)
Nebraska (25)
Nevada (82)
New Hampshire (65)
New Jersey (2156)
New Mexico (31)
New York (2138)
North Carolina (1172)
North Dakota (9)
Northern California (3261)
Ohio (244)
Oklahoma (17)
Oregon (37)
Pennsylvania (1604)
Puerto Rico (16)
Rhode Island (35)
South America (1380)
South Carolina (31)
South Dakota (1)
Southern California (2815)
Tennessee (127)
Texas (1150)
United States (28228)
Utah (225)
Virginia (195)
Washington D.C. (74)
Washington State (646)
West Virginia (4)
Wisconsin (77)
750,141 Results for "national institute of diabetes and digestive and kidney diseases niddk".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting
April 11, 2025
·
7 min read
Drug Development
Enable Biosciences Receives $3M Phase IIB SBIR Award from NIDDK for Advanced T1D Testing Technology
Enable Biosciences Inc. is elated to announce its receipt of a Phase IIB Small Business Innovation Research (SBIR) award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
December 19, 2023
·
2 min read
Press Releases
BioCity’s ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria
June 26, 2025
·
4 min read
BioMidwest
Semaglutide Reduced Risk for Major Kidney Disease Events by 24% for Patients with Type 2 Diabetes and Kidney Disease
Findings from the landmark FLOW trial, the first dedicated kidney outcomes trial with a GLP-1 receptor agonist were reported, demonstrating semaglutide significantly reduces the risk of major kidney disease events and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease.
June 24, 2024
·
4 min read
Biotech Beach
National Institute of Health to Fund Preclinical Development of Trethera Lead Drug, TRE-515, for Treatment of Crohn’s Disease
Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced today that it was awarded a Small Business Technology Transfer (STTR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) division of the National Institute of Health (NIH).
September 25, 2023
·
5 min read
Press Releases
NIMML Institute to Present Novel Clinical and Translational Data of Omilancor in Ulcerative Colitis Patients at Digestive Disease Week 2025
April 10, 2025
·
2 min read
Press Releases
ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200’s Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD)
June 26, 2025
·
6 min read
Press Releases
Celltrion to present six abstracts in inflammatory bowel disease (IBD) at 2025 Digestive Disease Week® (DDW)
April 28, 2025
·
16 min read
Press Releases
Intercept Announces Data to be Presented at Digestive Disease Week 2025
April 30, 2025
·
15 min read
Press Releases
FDA approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease
January 28, 2025
·
11 min read
1 of 75,015
Next